Open AccessIL‐17 expression as a possible predictive parameter for subclinical renal allograft rejection
Author(s) -
Hsieh H. G.,
Loong C. C.,
Lui W. Y.,
Chen A.,
Lin C. Y.
Publication year - 2001
Publication title -
transplant international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.998
H-Index - 82
eISSN - 1432-2277
pISSN - 0934-0874
DOI - 10.1111/j.1432-2277.2001.tb00062.x
Subject(s) - subclinical infection , medicine , creatinine , kidney , biopsy , transplantation , urinary system , renal function , urology , renal biopsy , kidney transplantation , blood urea nitrogen , nephrology , pathology , gastroenterology
Abstract In the present study we have tried to establish the role of IL‐17 in subclinical renal allograft rejection. In this animal model, renal grafts from BN (RT1 n ) were transplanted heterotopically into LEW (RT1 l ) rats. As controls, LEW grafts were transplanted into LEW rats. The histopathological examination demonstrated that the changes in the allograft kidney on day 2 were similar to those ranked as borderline changes according to the Banff classification scale. On day 2, the serum level of blood urea nitrogen (BUN) and creatinine were the same as on day 1. The examination of allograft cytokines mRNA showed that IL‐17 mRNA expressed earlier on the second postoperative day, peaked at day 5, and then declined, becoming almost undetectable at day 9, when most rats died. IL‐17 antigen was also proven, by histochemical staining, to be expressed early, however we could not find the same early appearance on other Th1/Th2 cytokines. In human renal biopsy samples, the IL‐17 antigen could be found scattered around in the borderline changed rejected renal allografts without evidence of a serum creatinine increase, but was undetectable both in normal controls and in renal transplant tissue without signs of rejection. IL‐17 mRNA was detected in the mononuclear cells of the urinary sediment of patients suffering from borderline subclinical rejection. From the above results we can hypothesize that IL‐17 could serve as a predictive parameter for borderline subclinical renal allograft rejection in the future.